3,4-Ethylidenedioxyamphetamine

3,4-Ethylidenedioxyamphetamine (3,4-EDA), also known as MDEA and by the street name Eve, is a psychoactive drug and amphetamine derivative that is closely related to MDMA (ecstasy). It is considered to be an entactogen and psychedelic drug, meaning it is known to produce feelings of empathy, love, and increased sociability alongside alterations in sensory perception. Unlike MDMA, however, 3,4-EDA has received less attention in both recreational and therapeutic contexts.

Chemistry

3,4-Ethylidenedioxyamphetamine is a synthetic molecule of the amphetamine class. Molecules of this class contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. 3,4-EDA, specifically, has an ethylene dioxy bridge connecting the 3 and 4 positions of the phenyl ring, which is a characteristic feature of the MDxx class of compounds.

Pharmacology

The pharmacological action of 3,4-EDA is primarily through its activity as a releasing agent of serotonin, dopamine, and norepinephrine, with the most significant effects on serotonin release. This action is responsible for its empathogenic effects. Its mechanism of action is similar to other drugs in its class, such as MDMA, but with potentially different potency and selectivity profiles.

Effects

The effects of 3,4-EDA can vary significantly among individuals but generally include euphoria, heightened senses, emotional openness, and a sense of well-being. Physical effects can include increased heart rate, elevated blood pressure, and dilated pupils. As with other substances in its class, the potential for negative side effects such as neurotoxicity, dehydration, and hyperthermia exists, particularly with high doses or frequent use.

Legal Status

The legal status of 3,4-EDA varies by country but it is often controlled under analog acts due to its structural and pharmacological similarities to MDMA. In many jurisdictions, it is illegal to manufacture, possess, or distribute without a license.

Research

Research on 3,4-EDA has been limited compared to MDMA. Studies that do exist have primarily focused on its pharmacological properties and potential neurotoxic effects. There is interest in the therapeutic potential of entactogens like 3,4-EDA for treating conditions such as PTSD and anxiety disorders, but more research is needed to fully understand its efficacy and safety.

See Also

• MDMA
• Amphetamine
• Psychedelic drug
• Entactogen